Home › Research › TREM2 and immune genetics
Diagnostic marker signature for esophageal cancer from transcriptome analysis
Warnecke-Eberz U, Metzger R, Hölscher AH, Drebber U, Bollschweiler E.. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015-12-02
Topic: Brain proteins, microglia and lab models
Esophageal cancer is often diagnosed at an advanced stage. Diagnostic markers are needed for achieving a cure in esophageal cancer detecting and treating tumor cells earlier. In patients with locally advanced squamous cell carcinoma of the esophagus (ESCC), we profiled the gene expression of ESCC compared to corresponding normal biopsies for diagnostic markers by genome microarrays.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Warnecke-Eberz, U., Metzger, R., Hölscher, A. H., Drebber, U., & Bollschweiler, E. (2016). Diagnostic marker signature for esophageal cancer from transcriptome analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. https://doi.org/10.1007/s13277-015-4400-4
Vancouver
Warnecke-Eberz U, Metzger R, Hölscher AH, Drebber U, Bollschweiler E. Diagnostic marker signature for esophageal cancer from transcriptome analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016. doi:10.1007/s13277-015-4400-4. PMID: 26631031.
BibTeX
@article{warneckeeberz2016-26631031,
author = {Warnecke-Eberz, U. and Metzger, R. and Hölscher, A. H. and Drebber, U. and Bollschweiler, E.},
title = {{Diagnostic marker signature for esophageal cancer from transcriptome analysis}},
journal = {Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine},
year = {2016},
doi = {10.1007/s13277-015-4400-4},
pmid = {26631031},
url = {https://doi.org/10.1007/s13277-015-4400-4}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Diagnostic markers are needed for achieving a cure in esophageal cancer detecting and treating tumor cells earlier.
- In patients with locally advanced squamous cell carcinoma of the esophagus (ESCC), we profiled the gene expression of ESCC compared to corresponding normal biopsies for diagnostic markers by genome microarrays.
- Profiling of gene expression identified 4844 genes differentially expressed, 2122 upregulated and 2722 downregulated in ESCC.
- Twenty-three overexpressed candidates with best scores from significance analysis have been selected for further analysis by TaqMan low-density array-technique using a validation cohort of 40 patients.
Why it matters
This study is about esophageal cancer, not Alzheimer's disease, so it has no direct meaning for treating, curing or preventing Alzheimer's. It identified genes differentially expressed in esophageal cancer for diagnostic marker purposes.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Participants19
- Evidence strengthModerate
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, so that was left out: it earned 43 of the 96 points we could judge it on, which is 45 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 19 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 72 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 6.0 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 3 / 6 | Cited 4.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 14 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Elfriede Bollschweiler: h-index 52 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Cologne: institution h-index 879 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 26631031) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 43 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 43 of the 96 points we could judge it on is 45 out of 100. |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in TREM2 and immune genetics
Also in TREM2 and immune genetics
95 studies in the library are filed under TREM2 and immune genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The TREM2 and immune genetics hub.